Thalidomide combined with chemo‑radiotherapy for treating esophageal cancer: A randomized controlled study

  • Authors:
    • Jian Wang
    • Jingping Yu
    • Jianlin Wang
    • Xinchu Ni
    • Zhiqiang Sun
    • Wei Sun
    • Suping Sun
    • Yuting Lu
  • View Affiliations

  • Published online on: May 14, 2019     https://doi.org/10.3892/ol.2019.10354
  • Pages: 804-813
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the efficiency and safety of a combination of thalidomide and chemo‑radiotherapy (CRT) for treating esophageal cancer (EC). Eligible patients received two cycles of chemotherapy using paclitaxel liposome and cisplatin concurrently with three‑dimensional radiotherapy. Following radiotherapy, two cycles of maintenance chemotherapy were performed. Patients with elevation of vascular endothelial growth factor (VEGF) during radiotherapy were randomly divided into: i) a test group (n=31), who received a combination of CRT and thalidomide; and ii) a control group (n=30), who received CRT only. Patients with locally advanced EC in the test group demonstrated a significantly improved 3‑year overall survival (OS) rate, progression‑free survival (PFS) rate, local control and median PFS time compared with the control group (P<0.05). Multivariate analysis indicated that Tumor‑Node‑Metastasis (TNM) stage was associated with the OS time, while TNM stage and the residence of cancer cells following radiotherapy were associated with PFS time. The present data indicate that thalidomide contributes to an improvement of prognosis for patients with locally advanced EC with elevated serum VEGF levels during radiotherapy. In addition, the toxicities induced by thalidomide were demonstrated to be tolerable.

References

1 

Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI

2 

DaVee T, Ajani JA and Lee JH: Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol. 23:751–762. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, et al: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI

4 

Zhao KL, Liu G, Jiang GL, Wang Y, Zhong LJ, Wang Y, Yao WQ, Guo XM, Wu GD, Zhu LX and Shi XH: Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiotherapy-a secondary analysis of three consecutive clinical phase III trials. Clin Oncol (R Coll Radiol). 18:621–627. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Maouris PG and Hirsch PJ: Pregnancy in women with thalidomide-induced disabilities. Case report and a questionnaire study. Br J Obstet Gynaecol. 95:717–719. 1988. View Article : Google Scholar : PubMed/NCBI

6 

Zhou S, Wang F, Hsieh TC, Wu JM and Wu E: Thalidomide-a notorious sedative to a wonder anticancer drug. Curr Med Chem. 20:4102–4108. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Rades D, Golke H, Schild SE and Kilic E: Impact of VEGF and VEGF receptor 1 (FLT1) expression on the prognosis of stage III esophageal cancer patients after radiochemotherapy. Strahlenther Onkol. 184:416–420. 2008. View Article : Google Scholar : PubMed/NCBI

8 

Yoon MS, Nam TK, Lee JS, Cho SH, Song JY, Ahn SJ, Chung IJ, Jeong JU, Chung WK and Nah BS: VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma. J Korean Med Sci. 26:513–520. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Yu J, Liu F, Sun M, Sun Z and Sun S: Enhancement of radiosensitivity and the potential mechanism on human esophageal carcinoma cells by tetrandrine. Cancer Biother Radiopharm. 26:437–442. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Yu J, Liu F, Sun Z, Sun M and Sun S: The enhancement of radiosensitivity in human esophageal carcinoma cells by thalidomide and its potential mechanism. Cancer Biother Radiopharm. 26:219–227. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Wang J, Yu JP, Wang JL, Ni XC, Sun ZQ, Sun W, Nie B, Jiang JT, Sun SP and Wu CP: Pathologic response and changes of serum VEGF during chemoradiotherapy may predict prognosis in non-surgical patients with esophageal carcinoma. Zhonghua Zhong Liu Za Zhi. 38:589–595. 2016.(In Chinese). PubMed/NCBI

12 

Yu JP, Sun SP, Sun ZQ, Ni XC, Wang J, Li Y, Hu LJ and Li DQ: Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer. World J Gastroenterol. 20:5098–5103. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Milstein JM, Cohen ME and Sinks LF: The influence and reliability of neurologic assessment and Karnofsky performance score on prognosis. Cancer 56 (7 Suppl). S1834–S1836. 1985. View Article : Google Scholar

14 

Strong VE, D'Amico TA, Kleinberg L and Ajani J: Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw. 11:60–66. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Coche E: Recist and beyond. JBR-BTR. 96:167–171. 2013.PubMed/NCBI

16 

Zhang TR, Zhao T, Xu X, Gu XW and Pan YK: Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy. Zhonghua Zhong Liu Za Zhi. 32:791–794. 2010.(In Chinese). PubMed/NCBI

17 

National Comprehensive Cancer Network, . NCCN. 2016.[EB/OL]. simplehttps://www.nccn.org/August 20–2016

18 

Crehange G, Maingon P, Peignaux K, N'guyen TD, Mirabel X, Marchal C, Verrelle P, Roullet B, Bonnetain F and Bedenne L; Federation Francophone de Cancerologie Digestive 9102, : Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation francophone de cancerologie digestive 9102. J Clin Oncol. 25:4895–4901. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Yu JP, Lu WB, Wang JL, Ni XC, Wang J, Sun ZQ and Sun SP: Pathologic response during chemo-radiotherapy and variation of serum VEGF levels could predict effects of chemo-radiotherapy in patients with esophageal cancer. Asian Pac J Cancer Prev. 16:1111–1116. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Lu JJ, Ma J, Miao R, Gu Y and Zhong FT: Expression of vascular endothelial growth factor D in human esophageal squamous cell carcinoma tissue and its significance. Zhonghua Wei Chang Wai Ke Za Zhi. 16:1191–1194. 2013.(In Chinese). PubMed/NCBI

21 

Bedoya F, Meneu JC, Macías MI, Moreno A, Enríquez-De-Salamanca R, Gonzalez EM and Vegh I: Mutation in CNR1 gene and VEGF expression in esophageal cancer. Tumori. 95:68–75. 2009. View Article : Google Scholar : PubMed/NCBI

22 

Srivastava VK, Gara RK, Rastogi N, Mishra DP, Ahmed MK, Gupta S, Goel MM and Bhatt ML: Serum vascular endothelial growth factor-A (VEGF-A) as a biomarker in squamous cell carcinoma of head and neck patients undergoing chemoradiotherapy. Asian Pac J Cancer Prev. 15:3261–3265. 2014. View Article : Google Scholar : PubMed/NCBI

23 

Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI

24 

Steins MB, Bieker R, Padró T, Kessler T, Kienast J, Berdel WE and Mesters RM: Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma. 44:1489–1493. 2003. View Article : Google Scholar : PubMed/NCBI

25 

Kay NE, Shanafelt TD, Call TG, Wu W and Laplant BR: N9986: A phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 50:588–592. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Townsend W, Johnson RJ, Pottinger BT, Counsell N, Smith P, Chadwick H, Evans K, Wickham C and Rudin CE; UK NCRI Lymphoma Clinical Studies Group, : A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320. Leuk Lymphoma. 57:2232–2234. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Kumar S, Witzig TE and Rajkumar SV: Thalidomid: Current role in the treatment of non-plasma cell malignancies. J Clin Oncol. 22:2477–2488. 2004. View Article : Google Scholar : PubMed/NCBI

28 

Rehman W, Arfons LM and Lazarus HM: The rise, fall and subsequent triumph of thalidomide: Lessons learned in drug development. Ther Adv Hematol. 2:291–308. 2011. View Article : Google Scholar : PubMed/NCBI

29 

Sauer H, Günther J, Hescheler J and Wartenberg M: Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am J Pathol. 156:151–158. 2000. View Article : Google Scholar : PubMed/NCBI

30 

Goel S, Wong AH and Jain RK: Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2:a0064862012. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2019
Volume 18 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, J., Yu, J., Wang, J., Ni, X., Sun, Z., Sun, W. ... Lu, Y. (2019). Thalidomide combined with chemo‑radiotherapy for treating esophageal cancer: A randomized controlled study. Oncology Letters, 18, 804-813. https://doi.org/10.3892/ol.2019.10354
MLA
Wang, J., Yu, J., Wang, J., Ni, X., Sun, Z., Sun, W., Sun, S., Lu, Y."Thalidomide combined with chemo‑radiotherapy for treating esophageal cancer: A randomized controlled study". Oncology Letters 18.1 (2019): 804-813.
Chicago
Wang, J., Yu, J., Wang, J., Ni, X., Sun, Z., Sun, W., Sun, S., Lu, Y."Thalidomide combined with chemo‑radiotherapy for treating esophageal cancer: A randomized controlled study". Oncology Letters 18, no. 1 (2019): 804-813. https://doi.org/10.3892/ol.2019.10354